The overall aim is to develop deoxynucleoside analogs for the treatment of patients with cancer. This includes the study of mechanism of action and resistance as well as the exploration of novel strategies to develop new nucleoside analogs with unique properties. In this application, we will continue to focus on the study of the anticancer action of a novel L-deoxynucleoside analog, L(-)dioxolane cytidine (L(-)OddC or BCH 4664) discovered in this laboratory and currently undergoing Phase II clinical studies. Based on the progress made, the Specific Aims are as follows: A. Study the role of AP endonuclease (APE/ref-I), which was identified to be the key activity in the removal of L(-)OddCMP from its 3'terminated DNA for the cytotoxic action of L(-)OddC. (1) Study the impact of unique mutations which could alter AP endonuclease activity or its redox regulatory activity, on its excision activity for the removal of L(-)OddCMP from its 3' -terminated DNA. (2) Study the impact of APE/ref-I, with or without unique mutations, on the action of L(-)OddC in cells. (3) Study the impact of thalidomide on the action of L(-)OddC with a focus on APE/ref-i expression. . Examine the functional role of CMP/UMP kinase for the phosphorylation of L(-)OddCMP or dCMP to their diphosphate nucleotide forms. (1) Examine the impact of altering CMP/UMP kinase protein expression in cells on dCyd or L(-)OddC metabolism. (2) Examine the possible alteration of the state of CMP/UMP kinase protein through post-translational modification or protein interaction in facilitating L(-)OddCMP or dCMP phosphorylation. (3) Examine the possible presence of dCMP kinase, which has not been identified, and its interaction with dCMP, CMP, UMP, L(-)OddCMP, AraCMP and dFdCydMP. The proposed study is based on some of the novel observations made during this funding period. It should provide information not only in terms of the action of all deoxycytidine analogs and their potential interaction with other classes of anticancer compounds, but also some basic knowledge regarding the biochemistry of nucleotide metabolism and DNA repair.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA063477-08
Application #
6633166
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Lees, Robert G
Project Start
1996-08-01
Project End
2006-05-30
Budget Start
2003-06-01
Budget End
2004-05-31
Support Year
8
Fiscal Year
2003
Total Cost
$271,410
Indirect Cost
Name
Yale University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Ye, Deyong; Shi, Qian; Leung, Chung-Hang et al. (2012) Antitumor agents 294. Novel E-ring-modified camptothecin-4?-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents. Bioorg Med Chem 20:4489-94
Zhang, Wei; Dutschman, Ginger E; Li, Xin et al. (2011) Quantitation of paclitaxel and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879:2018-22
Leung, Chung-Hang; Chan, Daniel Shiu-Hin; Man, Bradley Yat-Wah et al. (2011) Simple and convenient G-quadruplex-based turn-on fluorescence assay for 3' ? 5' exonuclease activity. Anal Chem 83:463-6
Zhang, Wei; Tan, Shenglan; Paintsil, Elijah et al. (2011) Analysis of deoxyribonucleotide pools in human cancer cell lines using a liquid chromatography coupled with tandem mass spectrometry technique. Biochem Pharmacol 82:411-7
Hu, Rong; Lam, Wing; Hsu, Chih-Hung et al. (2011) UMP/CMPK is not the critical enzyme in the metabolism of pyrimidine ribonucleotide and activation of deoxycytidine analogs in human RKO cells. PLoS One 6:e19490
Hines, John; Ju, Rong; Dutschman, Ginger E et al. (2010) Reversal of TNP-470-induced endothelial cell growth arrest by guanine and guanine nucleosides. J Pharmacol Exp Ther 334:729-38
Wang, Ying; Gao, Wenli; Svitkin, Yuri V et al. (2010) DCB-3503, a tylophorine analog, inhibits protein synthesis through a novel mechanism. PLoS One 5:e11607
Humeniuk, Rita; Menon, Lata G; Mishra, Prasun J et al. (2009) Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther 8:1037-44
Wang, Chuan-Jen; Lam, Wing; Bussom, Scott et al. (2009) TREX1 acts in degrading damaged DNA from drug-treated tumor cells. DNA Repair (Amst) 8:1179-89
Zhang, Wei; Dutschman, Ginger E; Li, Xin et al. (2009) Quantitation of Irinotecan and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometric. J Chromatogr B Analyt Technol Biomed Life Sci 877:3038-44

Showing the most recent 10 out of 38 publications